(GOSS) Gossamer Bio - Ratings and Ratios
Seralutinib, GB002
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 86.1% |
| Value at Risk 5%th | 129% |
| Relative Tail Risk | -9.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.70 |
| Alpha | 190.00 |
| CAGR/Max DD | 0.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.544 |
| Beta | 1.495 |
| Beta Downside | 2.393 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.63% |
| Mean DD | 56.04% |
| Median DD | 61.99% |
Description: GOSS Gossamer Bio January 01, 2026
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharma focused on inhaled therapies for pulmonary arterial hypertension (PAH). Its lead candidate, GB002 (formerly seralutinib), is a small-molecule inhibitor of PDGFR, CSF1R, and c-KIT currently in a Phase 3 trial in the United States, under a development and commercialization license with Pulmokine, Inc. The company, incorporated in 2015 and headquartered in San Diego, rebranded from FSG Bio in 2017.
As of the most recent 10-Q, Gossamer reported approximately $45 million of cash and marketable securities, giving it an estimated 12-month runway at current burn rates. The Phase 3 trial has enrolled over 80 % of its target population, and interim data showed a statistically significant improvement in 6-minute walk distance versus placebo. The stock trades at a market-cap of roughly $120 million, implying a price-to-cash-burn multiple of about 2.6×.
The PAH market is projected to reach $5 billion by 2028, driven by unmet clinical need and the premium pricing of novel inhaled agents. Biotech funding conditions remain favorable, with the U.S. FDA’s “Orphan Drug” and “Fast Track” designations historically boosting valuation multiples for niche-indication therapies.
For a deeper, data-driven view of GOSS’s valuation and risk profile, consider exploring the analyst toolkit on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -156.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.76 > 0.02 and ΔFCF/TA -75.51 > 1.0 |
| NWC/Revenue: 322.1% < 20% (prev 261.5%; Δ 60.54% < -1%) |
| CFO/TA -0.76 > 3% & CFO -158.4m > Net Income -156.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (228.0m) vs 12m ago 0.72% < -2% |
| Gross Margin: 97.56% > 18% (prev 0.97%; Δ 9659 % > 0.5%) |
| Asset Turnover: 15.74% > 50% (prev 31.95%; Δ -16.21% > 0%) |
| Interest Coverage Ratio: -13.45 > 6 (EBITDA TTM -146.0m / Interest Expense TTM 11.0m) |
Altman Z'' -15.00
| A: 0.68 (Total Current Assets 204.0m - Total Current Liabilities 62.1m) / Total Assets 208.8m |
| B: -6.66 (Retained Earnings -1.39b / Total Assets 208.8m) |
| C: -0.53 (EBIT TTM -147.6m / Avg Total Assets 279.8m) |
| D: -4.80 (Book Value of Equity -1.40b / Total Liabilities 291.2m) |
| Altman-Z'' Score: -25.85= D |
Beneish M -0.37
| DSRI: 3.73 (Receivables 9.64m/6.59m, Revenue 44.1m/112.1m) |
| GMI: 1.00 (GM 97.56% / 97.34%) |
| AQI: 2.42 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.39 (Revenue 44.1m / 112.1m) |
| TATA: 0.01 (NI -156.2m - CFO -158.4m) / TA 208.8m) |
| Beneish M-Score: -0.37 = D |
ValueRay F-Score (Strict, 0-100) 38.95
| 1. Piotroski: 1.50pt |
| 2. FCF Yield: -26.16% |
| 3. FCF Margin: data missing |
| 4. Debt/Equity: -2.46 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -76.70% |
| 7. RoE: 593.8% |
| 8. Revenue Trend: 77.99% |
| 9. EPS Trend: 81.95% |
What is the price of GOSS shares?
Over the past week, the price has changed by +17.14%, over one month by -23.87%, over three months by +29.86% and over the past year by +218.18%.
Is GOSS a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GOSS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 231% |
| Analysts Target Price | 9.5 | 231% |
| ValueRay Target Price | 3 | 4.9% |
GOSS Fundamental Data Overview January 19, 2026
P/B = 2.6638
Revenue TTM = 44.1m USD
EBIT TTM = -147.6m USD
EBITDA TTM = -146.0m USD
Long Term Debt = 198.3m USD (from longTermDebt, last quarter)
Short Term Debt = 919.0k USD (from shortTermDebt, last quarter)
Debt = 202.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 193.9m USD (from netDebt column, last quarter)
Enterprise Value = 605.9m USD (583.3m + Debt 202.9m - CCE 180.2m)
Interest Coverage Ratio = -13.45 (Ebit TTM -147.6m / Interest Expense TTM 11.0m)
EV/FCF = -3.82x (Enterprise Value 605.9m / FCF TTM -158.5m)
FCF Yield = -26.16% (FCF TTM -158.5m / Enterprise Value 605.9m)
FCF Margin = -359.8% (FCF TTM -158.5m / Revenue TTM 44.1m)
Net Margin = -354.5% (Net Income TTM -156.2m / Revenue TTM 44.1m)
Gross Margin = 97.56% ((Revenue TTM 44.1m - Cost of Revenue TTM 1.07m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 2.90 (Enterprise Value 605.9m / Total Assets 208.8m)
Interest Expense / Debt = 1.35% (Interest Expense 2.75m / Debt 202.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -116.6m (EBIT -147.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.28 (Total Current Assets 204.0m / Total Current Liabilities 62.1m)
Debt / Equity = -2.46 (negative equity) (Debt 202.9m / totalStockholderEquity, last quarter -82.3m)
Debt / EBITDA = -1.33 (negative EBITDA) (Net Debt 193.9m / EBITDA -146.0m)
Debt / FCF = -1.22 (negative FCF - burning cash) (Net Debt 193.9m / FCF TTM -158.5m)
Total Stockholder Equity = -26.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.80% (Net Income -156.2m / Total Assets 208.8m)
RoE = 593.8% (negative equity) (Net Income TTM -156.2m / Total Stockholder Equity -26.3m)
RoCE = -85.83% (EBIT -147.6m / Capital Employed (Equity -26.3m + L.T.Debt 198.3m))
RoIC = -67.95% (negative operating profit) (NOPAT -116.6m / Invested Capital 171.6m)
WACC = 8.75% (E(583.3m)/V(786.1m) * Re(11.42%) + D(202.9m)/V(786.1m) * Rd(1.35%) * (1-Tc(0.21)))
Discount Rate = 11.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.57%
Fair Price DCF = unknown (Cash Flow -158.5m)
EPS Correlation: 81.95 | EPS CAGR: 162.3% | SUE: 4.0 | # QB: 1
Revenue Correlation: 77.99 | Revenue CAGR: 26.11% | SUE: 0.89 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.21 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.60 | Chg30d=-0.013 | Revisions Net=-3 | Growth EPS=+17.2% | Growth Revenue=+6.4%
Additional Sources for GOSS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle